Vasopressin News and Research

RSS

Excessive salt intake 'reprograms' the brain, leads to hypertension

An international research team led by scientists at McGill University has found that excessive salt intake "reprograms" the brain, interfering with a natural safety mechanism that normally prevents the body's arterial blood pressure from rising.

23 Jan 2015

Discovery reveals promising target for treatment of end-stage heart failure

As a heart fails, losing its ability to squeeze blood through the circulatory system, the body releases a neurohormone that interferes with the heart's best chance to improve contractility, a team of Temple University School of Medicine researchers show in a study published September 9th in the American Heart Association journal, Circulation.

10 Sep 2014

Vasopressin more effective for cardiopulmonary resuscitation

Epinephrine has been shown to be a first-choice drug for cardiopulmonary resuscitation. Nevertheless, its β-adrenergic effect probably increases myocardial oxygen consumption and leads to severe cardiac and cerebral injuries; moreover, epinephrine does not elevate long-term survival rates.

29 Aug 2014

Researchers discover novel biomarker that could help predict preeclampsia

University of Iowa researchers have discovered a biomarker that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as 6 weeks into the pregnancy.

9 Jul 2014

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder.

11 Jun 2014

TUSM scientists receive $11.5M grant to develop innovative treatments for heart failure

Innovative treatments for heart failure are lacking, leaving the nearly six million Americans who suffer from the condition with little hope for a cure.

23 May 2014

Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. today announced the launch of its active promotional campaign to support its new Vaprisol® product.

7 May 2014

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

The discovery of a novel broad spectrum neuropeptide antagonist, peptide–1, which is related to the substance P analogue SP-G, could help develop treatments targeted at chemoresistant small-cell lung cancer, indicate study results.

1 Apr 2014

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

24 Mar 2014

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

5 Mar 2014

Study demonstrates impact of vitamin D on social behavior linked with ASD

A new study by Rhonda Patrick, PhD and Bruce Ames, PhD of Children's Hospital Oakland Research Institute (CHORI) demonstrates the impact that Vitamin D may have on social behavior associated with Autism Spectrum Disorder (ASD).

26 Feb 2014

CUMC researchers find potential target for treating autism, schizophrenia, and other brain disorders

Columbia University Medical Center (CUMC) researchers have determined that a small region of the hippocampus known as CA2 is essential for social memory, the ability of an animal to recognize another of the same species.

24 Feb 2014

Falling in love causes body to release feel-good chemicals that trigger specific physical reactions

Getting struck by Cupid's arrow may very well take your breath away and make your heart go pitter-patter this Valentine's Day, reports sexual wellness specialists at Loyola University Health System.

7 Feb 2014

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

27 Dec 2013

Combination therapy during cardiac arrest results in improved hospital discharge and neurological status

Among patients who experienced in-hospital cardiac arrest requiring vasopressors (drugs that increase blood pressure), use of a combination therapy during cardiopulmonary resuscitation resulted in improved survival to hospital discharge with favorable neurological status, according to a study in the July 17 issue of JAMA.

17 Jul 2013

Study: About 42% of screened veterans with blast injuries have irregular hormone levels

Up to 20 percent of veterans returning from Afghanistan and Iraq have experienced at least one blast concussion. New research suggests that nearly half these veterans may have a problem so under-recognized that even military physicians may fail to look for it.

23 Apr 2013

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease.

15 Apr 2013

Researchers discover new molecular mechanism to prevent edema formation

Researchers of the Max Delbr-ck Center for Molecular Medicine and the Leibniz Institute of Molecular Pharmacology in Berlin-Buch, Germany, have now detected a substance that can prevent the accumulation of fluid in body tissue and thus edema formation.

8 Apr 2013

Tolvaptan improves kidney health in polycystic kidney disease

A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.

12 Nov 2012

Study highlights potential treatment that reduces kidney growth

Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications.

5 Nov 2012